Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) Shares Outstanding (Diluted Average) (2020 - 2026)

Opus Genetics has reported Shares Outstanding (Diluted Average) over the past 7 years, most recently at $86.9 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 156.43% to $86.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $86.9 million through Mar 2026, up 156.43% year-over-year, with the annual reading at $62.2 million for FY2025, 132.91% up from the prior year.
  • Shares Outstanding (Diluted Average) was $86.9 million for Q1 2026 at Opus Genetics, up from $62.2 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $86.9 million in Q1 2026 and troughed at $18.9 million in Q1 2022.
  • The 5-year median for Shares Outstanding (Diluted Average) is $25.8 million (2024), against an average of $35.1 million.
  • Year-over-year, Shares Outstanding (Diluted Average) grew 9.13% in 2023 and then surged 170.17% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $19.6 million in 2022, then grew by 9.95% to $21.6 million in 2023, then increased by 23.74% to $26.7 million in 2024, then surged by 132.91% to $62.2 million in 2025, then skyrocketed by 39.65% to $86.9 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Shares Outstanding (Diluted Average) are $86.9 million (Q1 2026), $62.2 million (Q4 2025), and $70.6 million (Q3 2025).